Immunology | CHOP Research Institute


Published on
Jul 17, 2024
Dr. Sarah Henrickson identified a newborn’s immunodeficiency in 2015, and an international team characterized the rare disease this year.
Published on
May 15, 2023
This year’s Poster Day and Scientific Symposium featured all manners of bugs, breakthroughs, and big discoveries.
Published on
Mar 27, 2023
USIDNET will enhance its resources to improve the state of genetic diagnostics for patients with primary immunodeficiency diseases.
Published on
Jun 2, 2022
CHOP and Penn researchers discussed the latest findings about the mechanisms of immunity at the CHOP Research Institute 2022 Scientific Symposium.

Dr. Weber is developing approaches to enhance CAR-T cell therapies for pediatric cancer by reprogramming T cells with improved durability and exhaustion resistance. His work will uncover molecular mechanisms that promote CAR-T cell exhaustion and identify new targets for therapeutic intervention.

weberew [at]

Dr. Bailis aims to understand how metabolism underlies immunology and disease, by controlling the biochemistry of cells and tissues. His lab does so using in vitro and in vivo CRISPR engineering of primary human and mouse immune cells, with the goal of developing diet and metabolite based therapies.

bailisw [at]

The MAGIC Study is looking at the microbiome as it develops during the first two years of life. It brings together expertise in the microbiome, antibiotic stewardship, immunology, neonatology, and infectious diseases to study the effect that health and environment have on the microbiome and growth.

Evaluating interventions to treat and prevent HIV infection and its consequences in infants, children, adolescents, and pregnant/postpartum women through the conduct of high quality clinical trials.

The Oliver Lab focuses on revealing mechanisms governing T cell activation and protective immunity. Its goal is to define mechanisms that, when dysregulated, result in autoimmunity or allergic disorders like asthma.

Revealing new mechanistic insights into the multiple facets of why factor VIII inhibitors form as an immune response to protein replacement therapy to treat hemophilia A.